Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05651022 · ClinicalTrials.gov registry record · Phase 1

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

A Phase 1 study of Solid Tumor, Adult and Pancreatic Adenocarcinoma, sponsored by Indaptus Therapeutics.

Active
Registry status
Phase 1
Development phase
120
Enrollment target
12
Study locations

NCT05651022 is a Phase 1 study of Solid Tumor, Adult and Pancreatic Adenocarcinoma that is active but no longer recruiting, run by Indaptus Therapeutics. The registered enrollment target is 120 participants, below the 189-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (37% lower). The trial reports 12 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05651022, a Phase 1 study of Solid Tumor, Adult and Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by Indaptus Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
120 participants
Enrollment target
12
Study locations

Study Summary

INDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as monotherapy and in combination with tislelizumab in patients with locally advanced or metastatic solid tumors.

Conditions Studied

Solid Tumor, Adult Pancreatic Adenocarcinoma NSCLC (Non-small Cell Lung Cancer) CRC, Colorectal Cancer MSI-H Cancer UC (Urothelial Cancer) HCC - Hepatocellular Carcinoma Squamous Cell Cancer of the Head and Neck

Interventions

  • DRUG Tislelizumab
  • DRUG Decoy20

Study Locations (12)

Ohio

  • Gabrail Cancer & Research Center - Canton
  • UH Seidman Cancer Center - Cleveland
  • Cleveland Clinic Taussig Cancer Center - Cleveland

California

  • University of Southern California- Norris Cancer Center - Los Angeles
  • Hoag Memorial Hospital Presbyterian - Newport Beach

Georgia

  • Winship Cancer Institute of Emory University - Atlanta

Michigan

  • The Barbara Ann Karmanos Cancer Institute - Detroit

Missouri

  • Washington University, Siteman Cancer Center - St Louis

New Jersey

  • Atlantic Health System - Morristown

New York

  • Roswell Park Comprehensive Cancer Center - Buffalo

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2023-02-28
Est. Completion 2027-09-30
Phase Phase 1

Sponsor

Indaptus Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05651022

The ClinicalTrials.gov registry entry for NCT05651022 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (37% lower). The listed sponsor is Indaptus Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Solid Tumor, Adult appearing as the primary indexed condition, and to 2 interventions - of which Tislelizumab is the first listed.

NCT05651022 reports 12 study locations spanning 9 distinct geographic areas - top geographies include Ohio, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT05651022 about?

NCT05651022 is a clinical study titled "Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors". INDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as monotherapy and in combination with tislelizumab in patients with locally advanced or metastatic solid tumors.

What is the current status of trial NCT05651022?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2023-02-28. Estimated completion is 2027-09-30.

What conditions does trial NCT05651022 study?

This clinical trial studies the following conditions: Solid Tumor, Adult, Pancreatic Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC, Colorectal Cancer, MSI-H Cancer.

What interventions are being tested in trial NCT05651022?

The interventions under investigation include: Tislelizumab (DRUG), Decoy20 (DRUG).

Who is sponsoring clinical trial NCT05651022?

This trial is sponsored by Indaptus Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05651022 being conducted?

This trial has 12 study locations across California, Georgia, Michigan, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor, Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor, Adult

All registered trials for this condition

Pancreatic Adenocarcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.